ArticleKorean journal of pathology2013
EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast.
Article in Korean journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- EGFR Status by Immunohistochemistry in Triple-Negative Breast Cancer: An Evaluation of Prevalence and Association with Clinical and Pathological Parameters.Iranian journal of pathology · 2025Article
- Article
- The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast.Turk patoloji dergisi · 2020Article
- Improved characterization of the relationship between long intergenic non-coding RNA Linc00152 and the occurrence and development of malignancies.Cancer medicine · 2019Review
- Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome.Oncotarget · 2019Article
- A network pharmacology-based study on the anti-hepatoma effect of RadixChinese medicine · 2019Article
- Epidermal growth factor receptor (OncoTargets and therapy · 2019Article
- A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways.Molecular and cellular biochemistry · 2018Article
- Article
- Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.Scientific reports · 2017Article
- Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients.Journal of breast cancer · 2017Article
- mTOR function and therapeutic targeting in breast cancer.American journal of cancer research · 2017Review
- EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Molecular cancer therapeutics · 2016Article
- Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma.Oncology letters · 2015Article
- Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.British journal of cancer · 2015Article
- Immunohistochemical classification of primary and secondary glioblastomas.Korean journal of pathology · 2013Article
- A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.International journal of breast cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment.
methodsA total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification.
resultsEGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2(+), EGFR(+), cytokeratin 5/6(-) (CK5/6(-)) group, 11.2% of the HER-2(-), EGFR(+), CK5/6(-) group, and 19.1% of the HER-2(-), EGFR(+), CK5/6(+) group. FISH-positive cases were detected in 8.3% of the EGFR protein 1(+) expression cases, 15.9% of 2(+) expression cases, and 38.5% of 3(+) expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6.
conclusionsEGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.